{"schema_version":"secwatch.filing_event.v1","accession":"0001539497-24-000104","form_type":"8-K","ticker":null,"cik":"0001358403","company_name":"BELLICUM PHARMACEUTICALS, INC","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.944785+00:00","generated_at":"2026-06-06T19:09:39.321270+00:00","sec_items":["3.02","5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bellicum adjourns asset-sale special meeting for lack of quorum; issues super-voting share to director","bullets":["Special meeting to approve sale of assets (CaspaCIDe, iMC, GoCAR-T, Rimiducid) to MD Anderson and dissolution adjourned; only 4,132,740 shares present, short of quorum.","Issued one super-voting share to director Richard A. Fair for $0.01; holder casts votes proportionate to common stock votes at adjourned meeting.","Bylaws amended: quorum now requires majority of voting power present, not majority of outstanding shares.","No financial terms of asset sale disclosed; dissolution plan contingent on stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001539497-24-000104","json":"https://secwatch.observer/filing/0001539497-24-000104.json","markdown":"https://secwatch.observer/filing/0001539497-24-000104.md","text":"https://secwatch.observer/filing/0001539497-24-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/0001539497-24-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/n3936_x2-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:09:39.321270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65365f19ca4883141e3cbbfc652ff7ac30360fbb","claim":"BELLICUM PHARMACEUTICALS, INC: Amended Article III, Section 8 of bylaws to change quorum requirement to a majority of voting power rather than a majority of outstanding shares (effective 2024-01-24).","evidence_excerpt":"On January 24, 2024, the Board approved the amendment of Article III, Section 8 of the Company’s bylaws to enable the holders of a majority of the voting power of, rather than the majority of, the outstanding shares of stock of the Company entitled to vote at a meeting of stockholders to constitute a quorum for the transaction of business.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/0001539497-24-000104-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-01-24"}],"fact_type":"governance_change"},{"claim_id":"ac3df6c303a2bbe752d5b1049bb4e24d1c95a520","claim":"BELLICUM PHARMACEUTICALS, INC: Filed Certificate of Designation for Series A Junior Preferred Stock (Super-Voting Share) (effective 2024-01-24).","evidence_excerpt":"On January 24, 2024, the Company filed a Certificate of Designation of Series A Junior Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware with respect to the Super-Voting Share.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/0001539497-24-000104-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-24"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}